Core Insights - Prelude Therapeutics has received FDA clearance for the Investigational New Drug (IND) application for PRT12396, a mutant-selective JAK2V617F inhibitor, with a Phase 1 study expected to start in Q2 2026 [1][4] - The company is also advancing PRT13722, a highly-selective oral KAT6A degrader, with an IND filing anticipated in mid-2026 and Phase 1 study initiation planned for the second half of 2026 [1][5] - Prelude's current cash runway is projected to last into Q2 2027, with $106 million in cash and equivalents as of December 31, 2025 [1][14] R&D Pipeline Updates - The JAK2V617F mutation is a significant driver in myeloproliferative neoplasms (MPNs), affecting approximately 95% of polycythemia vera patients, 60% of essential thrombocythemia patients, and 55% of myelofibrosis patients [3] - Prelude has developed novel allosteric inhibitors targeting the JAK2 JH2 "deep pocket" where the V617F mutation resides, showing potential to reduce mutant allele burden and improve treatment outcomes for MPN patients [3] - The KAT6A oral degrader program targets ER+ breast cancer, with the potential for improved efficacy and tolerability compared to non-selective inhibitors [5] Financial Performance - For the year ended December 31, 2025, Prelude reported a net loss of $99.5 million, or $1.29 per share, a decrease from a net loss of $127.2 million, or $1.68 per share, in the previous year [17][21] - Research and development expenses decreased to $94.3 million from $118.0 million in the prior year, attributed to reduced stock-based compensation and discontinued clinical trials [15] - General and administrative expenses also decreased to $22.4 million from $28.7 million, primarily due to lower stock-based compensation and employee-related expenses [16] Upcoming Milestones - The Phase 1 study of PRT12396 will be an open-label, multi-center trial focusing on patients with high-risk polycythemia vera and intermediate to high-risk myelofibrosis [4] - Prelude plans to present initial preclinical data for its KAT6A program at upcoming conferences, showcasing its commitment to advancing its R&D pipeline [6][11] - The company will participate in the Citizens Life Sciences Conference on March 10, 2026, where key executives will discuss the company's strategic direction and upcoming milestones [12]

Core Insights - Prelude Therapeutics has received FDA clearance for its Investigational New Drug application (IND) for PRT12396, a mutant-selective JAK2V617F inhibitor, with a Phase 1 study expected to start in Q2 2026 [1][4] - The company is also advancing its KAT6A degrader program, with an IND filing anticipated in mid-2026 and a Phase 1 study initiation planned for the second half of 2026 [1][5] - Prelude's current cash runway is projected to extend into Q2 2027, with $106 million in cash and equivalents as of December 31, 2025 [1][14] R&D Pipeline Updates - The JAK2V617F mutation is prevalent in 95% of polycythemia vera (PV) patients, 60% of essential thrombocythemia (ET) patients, and 55% of myelofibrosis (MF) patients, making it a critical target for treatment [3] - Prelude has developed novel allosteric inhibitors that specifically target V617F+ cells, aiming to reduce mutant allele burden and improve treatment outcomes for patients with myeloproliferative neoplasms (MPNs) [3] - The KAT6A oral degrader program targets ER+ breast cancer, with the potential for improved efficacy and tolerability compared to non-selective inhibitors [5] Financial Performance - For the year ended December 31, 2025, Prelude reported a net loss of $99.5 million, or $1.29 per share, a decrease from a net loss of $127.2 million, or $1.68 per share, in the previous year [17][21] - Research and development expenses decreased to $94.3 million from $118.0 million in the prior year, attributed to reduced stock-based compensation and discontinued clinical trials [15] - General and administrative expenses also saw a decline to $22.4 million from $28.7 million, primarily due to lower stock-based compensation and employee-related expenses [16] Upcoming Milestones - The company is on track to have both PRT12396 and PRT13722 in clinical development in 2026, which may lead to significant data catalysts in 2027 [2] - Prelude will participate in the Citizens Life Sciences Conference on March 10, 2026, where key executives will discuss the company's progress and future plans [12]

Core Insights - Prelude Therapeutics has received FDA clearance to proceed with a Phase 1 study for PRT12396, a mutant-selective JAK2V617F inhibitor aimed at treating myeloproliferative neoplasms (MPNs) [1][2] - The company plans to begin dosing the first patient by Q2 of 2026, marking a significant milestone in its strategic focus on JAK2 and KAT6 programs [2] Company Developments - The Phase 1 study will be an open-label, multi-center trial assessing safety, efficacy, and pharmacokinetics in patients with high-risk polycythemia vera (PV) and intermediate to high-risk myelofibrosis (MF) [2] - Prelude's JAK2V617F inhibitor program is under an exclusive option agreement with Incyte, which was announced in November 2025 [3] Scientific Background - JAK2V617F is a key mutation affecting approximately 95% of patients with polycythemia vera, 60% of those with essential thrombocythemia, and 55% of myelofibrosis patients [4] - Prelude has developed novel allosteric inhibitors that specifically target V617F+ cells, which may reduce mutant allele burden and improve treatment outcomes for MPN patients [4] Company Overview - Prelude Therapeutics is focused on precision oncology, developing innovative medicines for cancer patients with high unmet needs [5] - The company's pipeline includes selective KAT6A degraders and JAK2V617F inhibitors, aiming to leverage targeted protein degradation for next-generation therapies [5]

Core Insights - Prelude Therapeutics has presented preclinical data on its JAK2V617F-selective JH2 inhibitors and mCALR-targeted degrader antibody conjugates at the American Society of Hematology (ASH) 67 Annual Meeting, highlighting their potential for disease modification in myeloproliferative neoplasms (MPNs) [1][2] JAK2V617F Inhibitor Program - PRT12396, a JAK2V617F-selective JH2 inhibitor, has shown robust preclinical activity, selectively inhibiting JAK2V617F while preserving wild-type JAK2 signaling, and demonstrated superior efficacy compared to ruxolitinib in multiple preclinical MPN models [2][4] - The company has completed GLP toxicology studies and plans to file an Investigational New Drug (IND) application and initiate a Phase 1 study in the first quarter of 2026 [3][4] - JAK2V617F mutation is present in approximately 95% of polycythemia vera (PV) patients, 60% of essential thrombocythemia (ET) patients, and 55% of myelofibrosis (MF) patients, making it a critical target for treatment [5][6] mCALR-targeted Degrader Antibody Conjugates - The company has introduced a novel mCALR-targeted degrader antibody conjugate (DAC) that delivers a CDK9 degrader payload selectively to malignant cells, demonstrating deep mutant-selective killing and sparing healthy hematopoietic cells [4][7] - mCALR is found in approximately 25-35% of patients with MF and ET, and recent clinical data has shown meaningful therapeutic benefits from mCALR-directed antibodies [7][8] Company Overview - Prelude Therapeutics is focused on developing innovative precision oncology medicines, with a pipeline that includes selective KAT6A degraders and JAK2V617F-selective JH2 inhibitors, aiming to address high unmet needs in cancer treatment [8]

Core Insights - Prelude Therapeutics has presented preclinical data on its JAK2V617F-selective JH2 inhibitors and mCALR-targeted degrader antibody conjugates at the American Society of Hematology (ASH) 67th Annual Meeting, highlighting their potential for disease modification in myeloproliferative neoplasms (MPNs) [1][2][4] JAK2V617F Inhibitor Program - PRT12396, a JAK2V617F-selective JH2 inhibitor, has shown robust preclinical activity, selectively inhibiting JAK2V617F while preserving wild-type JAK2 signaling, and demonstrated superior efficacy compared to ruxolitinib in multiple preclinical MPN models [2][3][6] - The company has completed GLP toxicology studies and plans to file an Investigational New Drug (IND) application and initiate a Phase 1 study in the first quarter of 2026 [3][6] - JAK2V617F mutation is present in approximately 95% of polycythemia vera (PV) patients, 60% of essential thrombocythemia (ET) patients, and 55% of myelofibrosis (MF) patients, making it a critical target for treatment [5][6] mCALR Degrader Antibody Conjugate Program - The company has introduced a novel mCALR-targeted degrader antibody conjugate (DAC) that delivers a CDK9 degrader payload selectively to malignant cells, demonstrating deep mutant-selective killing and sparing healthy hematopoietic cells [4][7] - mCALR is found in approximately 25-35% of patients with MF and ET, and recent clinical data has shown meaningful therapeutic benefits from mCALR-directed antibodies [7] Company Overview - Prelude Therapeutics is focused on developing innovative precision oncology medicines, including selective KAT6A degraders and JAK2V617F-selective JH2 inhibitors, aiming to address high unmet needs in cancer treatment [8]